BRIEF-Orchestra Biomed Receives FDA Approval Of Ide To Initiate U.S. Coronary Pivotal Trial Randomizing First-In-Class Sirolimus-Angioinfusion Balloon, Virtue Sab, Head-To-Head With Paclitaxel-Coated Balloon

Reuters

29 Apr

BRIEF-Orchestra Biomed Receives FDA Approval Of Ide To Initiate U.S. Coronary Pivotal Trial Randomizing First-In-Class Sirolimus-Angioinfusion Balloon, Virtue Sab, Head-To-Head With Paclitaxel-Coated Balloon

April 29 (Reuters) - Orchestra Biomed Holdings Inc OBIO.O:

ORCHESTRA BIOMED RECEIVES FDA APPROVAL OF IDE TO INITIATE U.S. CORONARY PIVOTAL TRIAL RANDOMIZING FIRST-IN-CLASS SIROLIMUS-ANGIOINFUSION BALLOON, VIRTUE SAB, HEAD-TO-HEAD WITH PACLITAXEL-COATED BALLOON
ORCHESTRA BIOMED HOLDINGS INC: TARGETING INITIATION OF VIRTUE TRIAL DURING SECOND HALF OF 2025

Source text: ID:nGNX9CRyqk

Further company coverage: OBIO.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2531340677"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2531340677\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2531340677?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-29 21:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2531340677","market":"us","top_or_hot":-1,"title":"BRIEF-Orchestra Biomed Receives FDA Approval Of Ide To Initiate U.S. Coronary Pivotal Trial Randomizing First-In-Class Sirolimus-Angioinfusion Balloon, Virtue Sab, Head-To-Head With Paclitaxel-Coated Balloon","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Orchestra Biomed Receives FDA Approval Of Ide To Initiate U.S. Coronary Pivotal Trial Randomizing First-In-Class Sirolimus-Angioinfusion Balloon, Virtue Sab, Head-To-Head With Paclitaxel-Coated Balloon</title></head><body><p><span>April 29 (Reuters)</span><span> - </span>Orchestra Biomed Holdings Inc <span>OBIO.O</span>:</p><ul><li><p>ORCHESTRA BIOMED RECEIVES FDA APPROVAL OF IDE TO INITIATE U.S. CORONARY PIVOTAL TRIAL RANDOMIZING FIRST-IN-CLASS SIROLIMUS-ANGIOINFUSION BALLOON, VIRTUE SAB, HEAD-TO-HEAD WITH PACLITAXEL-COATED BALLOON</p></li><li><p>ORCHESTRA BIOMED HOLDINGS INC: TARGETING INITIATION OF VIRTUE TRIAL DURING SECOND HALF OF 2025</p></li></ul><p>Source text: <span>ID:nGNX9CRyqk</span></p><p>Further company coverage: <span>OBIO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Orchestra Biomed Receives FDA Approval Of Ide To Initiate U.S. Coronary Pivotal Trial Randomizing First-In-Class Sirolimus-Angioinfusion Balloon, Virtue Sab, Head-To-Head With Paclitaxel-Coated Balloon</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Orchestra Biomed Receives FDA Approval Of Ide To Initiate U.S. Coronary Pivotal Trial Randomizing First-In-Class Sirolimus-Angioinfusion Balloon, Virtue Sab, Head-To-Head With Paclitaxel-Coated Balloon\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-04-29 21:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Orchestra Biomed Receives FDA Approval Of Ide To Initiate U.S. Coronary Pivotal Trial Randomizing First-In-Class Sirolimus-Angioinfusion Balloon, Virtue Sab, Head-To-Head With Paclitaxel-Coated Balloon</title></head><body><p><span>April 29 (Reuters)</span><span> - </span>Orchestra Biomed Holdings Inc <span>OBIO.O</span>:</p><ul><li><p>ORCHESTRA BIOMED RECEIVES FDA APPROVAL OF IDE TO INITIATE U.S. CORONARY PIVOTAL TRIAL RANDOMIZING FIRST-IN-CLASS SIROLIMUS-ANGIOINFUSION BALLOON, VIRTUE SAB, HEAD-TO-HEAD WITH PACLITAXEL-COATED BALLOON</p></li><li><p>ORCHESTRA BIOMED HOLDINGS INC: TARGETING INITIATION OF VIRTUE TRIAL DURING SECOND HALF OF 2025</p></li></ul><p>Source text: <span>ID:nGNX9CRyqk</span></p><p>Further company coverage: <span>OBIO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nTUA83BYJP:1","article_id":"2531340677","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2531340677","pubTimestamp":1745932804,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Orchestra Biomed Receives FDA Approval Of Ide To Initiate U.S. Coronary Pivotal Trial Randomizing First-In-Class Sirolimus-Angioinfusion Balloon, Virtue Sab, Head-To-Head With Paclitaxel-Coated ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","OBIO":"Orchestra BioMed"},"translate_title":"BRIEF-Orchestra Biomed获得FDA批准Ide启动美国冠状动脉关键试验，将一流的西罗莫司血管灌注球囊Virtue Sab与紫杉醇涂层球囊进行随机分组","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OBIO":0.9},"content_text":"BRIEF-Orchestra Biomed Receives FDA Approval Of Ide To Initiate U.S. Coronary Pivotal Trial Randomizing First-In-Class Sirolimus-Angioinfusion Balloon, Virtue Sab, Head-To-Head With Paclitaxel-Coated BalloonApril 29 (Reuters) - Orchestra Biomed Holdings Inc OBIO.O:ORCHESTRA BIOMED RECEIVES FDA APPROVAL OF IDE TO INITIATE U.S. CORONARY PIVOTAL TRIAL RANDOMIZING FIRST-IN-CLASS SIROLIMUS-ANGIOINFUSION BALLOON, VIRTUE SAB, HEAD-TO-HEAD WITH PACLITAXEL-COATED BALLOONORCHESTRA BIOMED HOLDINGS INC: TARGETING INITIATION OF VIRTUE TRIAL DURING SECOND HALF OF 2025Source text: ID:nGNX9CRyqkFurther company coverage: OBIO.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}